https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Virtual histology of cortical thickness and shared neurobiology in 6 psychiatric disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43667 Wed 28 Sep 2022 13:52:58 AEST ]]> Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings A Systematic Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53446 Wed 28 Feb 2024 15:25:40 AEDT ]]> Problems with the interpretation of pharmacoeconomic analyses https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2842 Wed 24 Jul 2013 22:50:47 AEST ]]> Association of polipoprotein E with intracerebral hemorrhage risk by race/ethnicity a meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48569 Wed 22 Mar 2023 15:26:43 AEDT ]]> Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47094 Wed 14 Dec 2022 09:37:30 AEDT ]]> Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men with Nonmetastatic Prostate Cancer in Australia and New Zealand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40374 Wed 13 Mar 2024 08:55:36 AEDT ]]> Preventing obesity among adolescent girls: one-year outcomes of the Nutrition and Enjoyable Activity for Teen Girls (NEAT Girls) cluster randomized controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11906 Wed 11 Apr 2018 16:12:48 AEST ]]> Analyzing the role of microRNAs in schizophrenia in the context of common genetic risk variants https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29013 P < 2 × 10−16). Further, the gene set analyses revealed several miRNAs regulating schizophrenia risk genes, with the strongest enrichment for targets of miR-9-5p (P = .0056 for enrichment among the top 1% most-associated single-nucleotide polymorphisms, corrected for multiple testing). It is further of note that MIR9-2 is located in a genomic region showing strong evidence for association with schizophrenia (P = 7.1 × 10−8). The second and third strongest gene set signals were seen for the targets of miR-485-5p and miR-137, respectively. Conclusions and Relevance: This study provides evidence for a role of miR-9-5p in the etiology of schizophrenia. Its implication is of particular interest as the functions of this neurodevelopmental miRNA tie in with established disease biology: it has a regulatory loop with the fragile X mental retardation homologue FXR1 and regulates dopamine D2 receptor density.]]> Wed 11 Apr 2018 15:28:50 AEST ]]> Reducing inappropriate polypharmacy: the process of deprescribing https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27968 Wed 11 Apr 2018 14:26:18 AEST ]]> Assessing response to stroke thrombolysis validation of 24-hour multimodal magnetic resonance imaging https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22216 Wed 11 Apr 2018 14:00:50 AEST ]]> Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14089 Wed 11 Apr 2018 11:59:36 AEST ]]> Associations between methylenetetrahydrofolate reductase polymorphisms, serum homocysteine levels, and incident cortical cataract https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29933 15 µmol/L: OR = 2.24; 95% CI = 1.38-3.63) were independently associated with increased risk of cortical cataract. Path analysis showed that the genetic effect on cortical cataract was partially mediated via homocysteine levels. Combined CT/TT genotypes and elevated homocysteine levels were associated with a 3-fold risk of cortical cataract (OR = 3.74; 95% CI = 1.79-7.80). The synergy index of both exposures was 1.34 (95% CI = 0.44-4.01). Conclusions and Relevance: MTHFR polymorphism and elevated homocysteine levels contributed separately and jointly to increased risk of cortical cataract. If these findings are confirmed, homocysteine levels may be a therapeutic target to reduce risk of cortical cataract in persons carrying genetic risk.]]> Wed 10 Nov 2021 15:04:55 AEDT ]]> Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50847 Wed 09 Aug 2023 09:32:29 AEST ]]> Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling after Myocardial Infarction: A Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49049 Wed 03 May 2023 15:40:36 AEST ]]> Effect of a Scalable School-Based Intervention on Cardiorespiratory Fitness in Children: A Cluster Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49038 Wed 03 May 2023 13:48:10 AEST ]]> Association of Structural Magnetic Resonance Imaging Measures with Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49020 Wed 03 May 2023 12:31:22 AEST ]]> Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54499 Tue 27 Feb 2024 15:18:23 AEDT ]]> Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13824 Tue 24 Aug 2021 14:27:34 AEST ]]> Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21585 Tue 17 Nov 2015 14:40:08 AEDT ]]> Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> Surgical Plating vs Closed Reduction for Fractures in the Distal Radius in Older Patients: A Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49854 Tue 06 Jun 2023 14:56:50 AEST ]]> Low-dose vs standard-dose alteplase for patients with acute ischemic stroke: secondary analysis of the ENCHANTED randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32180 .37 for interaction). Similarly, the treatment effects of low- vs standard-dose alteplase on function outcome (ordinal shift of the modified Rankin Scale) in Asians (odds ratio, 1.05; 95% CI, 0.90-1.22) was consistent with non-Asians (odds ratio, 0.93; 95% CI, 0.76-1.14) (P = .32 for interaction). There were generally consistent reductions in rates of symptomatic intracerebral hemorrhage with low-dose alteplase, although this reduction was not statistically significant by age, ethnicity, or severity. Conclusions and Relevance: This analysis found that the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability in key demographic subgroups of patients with AIS. Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase. Trial Resgistration: clinicaltrials.gov Identifier: NCT01422616.]]> Thu 27 Jan 2022 15:56:56 AEDT ]]> Mediation Analysis to Untangle Opposing Associations of High-Dose Docosahexaenoic Acid With IQ and Bronchopulmonary Dysplasia in Children Born Preterm https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52758 Thu 26 Oct 2023 12:05:26 AEDT ]]> Analysis of Rates of Completion, Delays, and Participant Recruitment in Randomized Clinical Trials in Surgery https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49975 Thu 22 Jun 2023 11:31:53 AEST ]]> A guideline for reporting mediation analyses of randomized trials and observational studies: the AGReMA statement https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49453 Thu 18 May 2023 11:23:00 AEST ]]> Association of Topical Corticosteroids with Reduced Vulvar Squamous Cell Carcinoma Recurrence in Patients with Vulvar Lichen Sclerosus https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42952 Thu 08 Sep 2022 14:36:29 AEST ]]> Effect of Cytisine vs Varenicline on Smoking Cessation A Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40305 Thu 07 Jul 2022 16:14:44 AEST ]]> Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45527 1c level of 5.7% to 6.4% or fasting plasma glucose level of 100 mg/dL to 125 mg/dL (to convert to mmol/L, multiply by 0.0555). Good adherence was defined as taking 80% or more of the protocol dose. Fasting glucose and hemoglobin A1c, used to define prediabetes, and adherence of 80% or higher, stipulated in the protocol as defining good adherence, were prespecified subgroups in the analysis plan. Interventions: Participants were randomized to 15 mg of pioglitazone, with dose titrated to target of 45 mg daily, or matching placebo. Main Outcomes and Measures: The primary outcome was recurrent stroke or MI. Secondary outcomes included stroke, acute coronary syndrome, stroke/MI/hospitalization for heart failure, and progression to diabetes. Results: Among 3876 participants analyzed in the IRIS trial, 2885 were included in this analysis (1456 in the pioglitazone cohort and 1429 in the placebo cohort). The mean (SD) age of patients was 64 (11) years, and 974 (66.9%) and 908 (63.5%) of patients were men in the pioglitazone and placebo cohort, respectively. In the prediabetic population with good adherence (644 of 1456 individuals [44.2%] in the pioglitazone group and 810 of 1429 [56.7%] in the placebo group), the hazard ratios (95% CI) were 0.57 (0.39-0.84) for stroke/MI, 0.64 (0.42-0.99) for stroke, 0.47 (0.26-0.85) for acute coronary syndrome, 0.61 (0.42-0.88) for stroke/MI/hospitalization for heart failure, and 0.18 (0.10-0.33) for progression to diabetes. There was a nonsignificant reduction in overall mortality, cancer, and hospitalization, a slight increase in serious bone fractures, and an increase in weight gain and edema. Intention-to-treat results also showed significant reduction of events but to a lesser degree. Hazard ratios (95% CI) were 0.70 (0.56-0.88) for stroke/MI, 0.72 (0.56-0.92) for stroke, 0.72 (0.52-1.00) for acute coronary syndrome, 0.78 (0.63-0.96), for stroke/MI/hospitalization for heart failure, and 0.46 (0.35 to 0.61) for progression to diabetes. Conclusions and Relevance: Pioglitazone may be effective for secondary prevention in patients with stroke/transient ischemic attack and with prediabetes, particularly in those with good adherence. Trial Registration: ClinicalTrials.gov identifier: NCT00091949]]> Thu 03 Nov 2022 15:05:53 AEDT ]]> How to use an article about genetic association. A: background concepts https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7491 Sat 24 Mar 2018 08:37:45 AEDT ]]> How to use an article about genetic association. B: are the results of the study valid? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7490 Sat 24 Mar 2018 08:37:45 AEDT ]]> How to use an article about genetic association. C: what are the results and will they help me in caring for my patients? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7492 Sat 24 Mar 2018 08:37:45 AEDT ]]> The relationship between psychiatric illnesses and skin disease: a longitudinal analysis of young Australian women https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8324 Sat 24 Mar 2018 08:36:55 AEDT ]]> Randomized controlled trial of proactive web-based alcohol screening and brief intervention for university students https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8215 Sat 24 Mar 2018 08:36:21 AEDT ]]> Is quality of care only instrumental? (letter) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7654 Sat 24 Mar 2018 08:35:59 AEDT ]]> Cardiovascular risk and inhibition of cyclooxygenase - a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1296 Sat 24 Mar 2018 08:32:44 AEDT ]]> Measuring effectiveness of dietetic interventions in child obesity: a systematic review of randomized trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1129 Sat 24 Mar 2018 08:32:00 AEDT ]]> Does this patient have pulmonary embolism? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1671 Sat 24 Mar 2018 08:30:24 AEDT ]]> Consumption of NSAIDs and the development of congestive heart failure in elderly patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2835 Sat 24 Mar 2018 08:29:17 AEDT ]]> Tomato juice and platelet aggregation in type 2 diabetes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1694 Sat 24 Mar 2018 08:27:22 AEDT ]]> Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2260 US $382; odds ratio [OR], 3.5; 95% confidence interval [CI], 2.6-4.7) and support for attending international conferences (OR, 5.4; 95% CI, 3.9-7.4). The strongest associations were seen for acting as a paid consultant to industry (OR, 9.0; 95% CI, 3.9-20.4) and for membership on advisory boards (OR, 6.9; 95% CI, 5.1-9.6). There was a strong relationship between research collaboration and accumulation of industry ties. For 1 additional tie the OR was 2.2 (95% CI, 1.2-3.8) and rose to 6.3 (95% CI, 3.5-11.1) with 3 ties and 41.8 (95% CI, 14.5-143.4) with 6 or more ties. Conclusions: Medical specialists who have research relationships with the pharmaceutical industry are much more likely to have multiple additional ties than those who do not have research relationships. Institutional review should discourage clinical researchers from developing multiple ties.]]> Sat 24 Mar 2018 08:27:17 AEDT ]]> Mission to eliminate postinjury abdominal compartment syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14324 Sat 24 Mar 2018 08:26:22 AEDT ]]> Physical activity intensity and cardiometabolic risk in youth https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20708 2max]). Results: Body mass index z score, waist circumference, and systolic blood pressure decreased and [Vdot]O2max increased in a dose-response manner across tertiles of vigorous PA (adjusted P < .001). No significant differences in cardiometabolic risk factors were seen across tertiles of moderate or light PA in multivariable analyses. Achieving more than 7 minutes of vigorous PA daily was associated with a reduced adjusted odds ratio of overweight status (0.56; 95% CI, 0.33-0.95) and elevated systolic blood pressure (0.36; 95% CI, 0.16-0.79). The odds of overweight status and elevated blood pressure decreased with increasing time and intensity of PA. Conclusions: Only vigorous PA was consistently associated with lower levels of waist circumference, body mass index z score, systolic blood pressure, and increased cardiorespiratory fitness in youth. These findings underscore the importance of vigorous PA in guidelines for children and adolescents.]]> Sat 24 Mar 2018 08:06:22 AEDT ]]> Management of chronic prostatitis/ chronic pelvic pain syndrome: a systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18172 Sat 24 Mar 2018 08:04:34 AEDT ]]> Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17133 Sat 24 Mar 2018 08:02:30 AEDT ]]> Acupuncture for chronic knee pain a randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19608 Sat 24 Mar 2018 07:58:23 AEDT ]]> Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19106 Sat 24 Mar 2018 07:55:58 AEDT ]]> Web-based alcohol screening and brief intervention for university students: A randomized trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18536 Sat 24 Mar 2018 07:50:11 AEDT ]]> Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18570 Sat 24 Mar 2018 07:50:10 AEDT ]]> Evidence for genetic overlap between schizophrenia and age at first birth in women. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29862 2 = 1.1E-03, P = 4.1E-04), reflecting the published relationship between maternal age and SCZ risk in offspring by McGrath et al in 2014. Conclusions and Relevance: This study provides evidence for a significant overlap between genetic factors associated with risk of SCZ and genetic factors associated with AFB. It has been reported that SCZ risk associated with increased maternal age is explained by the age of the father and that de novo mutations that occur more frequently in the germline of older men are the underlying causal mechanism. This explanation may need to be revised if, as suggested herein and if replicated in future studies, there is also increased genetic risk of SCZ in older mothers.]]> Sat 24 Mar 2018 07:40:47 AEDT ]]> Association of pembrolizumab with tumor response and survival among patients with advanced melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29369 Sat 24 Mar 2018 07:34:17 AEDT ]]> Identifying otolaryngology systematic review research gaps: comparing global burden of disease 2010 results with cochrane database of systematic review content https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26893 Sat 24 Mar 2018 07:23:33 AEDT ]]> Guest authorship, mortality reporting, and integrity in rofecoxib studies (letter) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4461 Sat 24 Mar 2018 07:18:29 AEDT ]]> Myopia, lifestyle, and schooling in students of Chinese ethnicity in Singapore and Sydney https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4463 Sat 24 Mar 2018 07:18:29 AEDT ]]> Randomized controlled trial of web-based alcohol screening and brief intervention in primary care https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4462 Sat 24 Mar 2018 07:18:29 AEDT ]]> Interventions by health care professionals who provide routine child health care to reduce tobacco smoke exposure in children a review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24406 Sat 24 Mar 2018 07:14:24 AEDT ]]> Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24111 Sat 24 Mar 2018 07:11:41 AEDT ]]> Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children with Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50299 Sat 15 Jul 2023 12:18:12 AEST ]]> Association between early contact with mental health services after an offense and reoffending in individuals diagnosed with psychosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38394 Mon 29 Jan 2024 17:47:23 AEDT ]]> Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> Diseases, injuries, and risk factors in child and adolescent health, 1990 to 2017: findings from the global burden of diseases, injuries, and risk factors 2017 study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48517 Mon 20 Mar 2023 17:01:04 AEDT ]]> Management of Acute Coronary Syndromes in Patients in Rural Australia: The MORACS Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50968 Mon 14 Aug 2023 15:20:39 AEST ]]> Nabiximols for the treatment of cannabis dependence: a randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46876 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) and were seeking treatment, were nonresponsive to prior treatment attempts, were 18 to 64 years of age, had no other substance use disorder, had no severe medical or psychiatric conditions, were not pregnant, were not mandated by a court to undergo treatment, and provided informed consent. Results for primary efficacy measures and all secondary outcomes were obtained using a modified intention-to-treat data set. Interventions: Participants received 12-week treatment involving weekly clinical reviews, structured counseling, and flexible medication doses - up to 32 sprays daily (tetrahydrocannabinol, 86.4 mg, and cannabidiol, 80 mg), dispensed weekly. Main Outcomes and Measures: Primary outcome was self-reported number of days using illicit cannabis during the 12-week period. Other outcomes included alternate cannabis use parameters (periods of abstinence, withdrawal, cravings, and problems), safety parameters (adverse events and aberrant medication use), health status, other substance use, and treatment retention. Results: A total of 128 participants (30 women and 98 men; mean [SD] age, 35.0 [10.9] years) were randomized and received at least 1 dose of study medication. Participants had used a mean (SD) of 2.3 (2.1) g of cannabis on a mean (SD) of 25.7 (4.5) days in the past 28 days. Treatment retention was comparable for the 2 groups (placebo, 30 of 67 participants [44.8%]; nabiximols, 30 of 61 participants [49.2%]), and both groups used similar mean (SD) doses (placebo, 18.5 [9.5] sprays daily; nabiximols, 17.6 [9.5] sprays daily, equivalent to a mean [SD] of 47.5 [25.7] mg of tetrahydrocannabinol and 44.0 [23.8] mg of cannabidiol). For the primary end point, the placebo group reported significantly more days using cannabis during the 12 weeks (mean [SD], 53.1 [33.0] days) than the nabiximols group (mean [SD], 35.0 [32.4] days; estimated difference, 18.6 days; 95% CI, 3.5-33.7 days; P =.02). Both groups showed comparable improvements in health status, with no substantial changes in other substance use. Medication was well tolerated with few adverse events. Conclusions and Relevance: This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment. Trial Registration: anzctr.org.au Identifier: ACTRN12616000103460.]]> Mon 05 Dec 2022 09:33:25 AEDT ]]> Neurobiological, Psychosocial, and Behavioral Mechanisms Mediating Associations Between Physical Activity and Psychiatric Symptoms in Youth in the Netherlands https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51400 Mon 04 Sep 2023 14:51:42 AEST ]]> Plating vs Closed Reduction for Fractures in the Distal Radius in Older Patients: A Secondary Analysis of a Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48081 Fri 24 Feb 2023 14:27:56 AEDT ]]> Association of Pregnancy with the Onset of Clinically Isolated Syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5-to 9-Hours and Wake-Up Stroke Time Window A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41084 Fri 22 Jul 2022 17:11:20 AEST ]]> Association of Schizophrenia Risk with Disordered Niacin Metabolism in an Indian Genome-wide Association Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49494 Fri 19 May 2023 10:52:01 AEST ]]> Effect of Treatment of Clinical Seizures vs Electrographic Seizures in Full-Term and Near-Term Neonates: A Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53197 Fri 17 Nov 2023 11:52:45 AEDT ]]> Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47334 Fri 13 Jan 2023 11:55:34 AEDT ]]> Leisure-Time Physical Activity and Falls With and Without Injuries Among Older Adult Women https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54677 Fri 08 Mar 2024 11:38:23 AEDT ]]> Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants with Treatment Resistance in Schizophrenia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49142 Fri 05 May 2023 12:07:01 AEST ]]> Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage i endometrial cancer: a randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34127 Fri 03 Dec 2021 10:32:07 AEDT ]]>